The Biden administration has today taken a significant step towards addressing the affordability of prescription drugs for older Americans.
Recent changes to the Medicare bill allow Medicare to engage in direct price negotiations with pharmaceutical manufacturers.
Scheduled to be implemented in 2026, the prices agreed upon during these negotiations will apply to the initial set of 10 prescription drugs. The aim is to alleviate the financial burden associated with expensive medications and promote accessibility for the elderly.
Here is the list of the 10 drugs that will be subject to the initial negotiations this year:
- Eliquis by Bristol-Myers Squibb (NYSE: BMY );
- Jardiance by Boehringer Ingelheim;
- Xarelto by Johnson & Johnson (NYSE: JNJ );
- Januvia by Merck (NYSE: MRK );
- Farxiga by AstraZeneca (NASDAQ: AZN );
- Entresto by Novartis (NYSE: NVS );
- Enbrel by Amgen (NASDAQ: AMGN );
- Imbruvica by AbbVie (NYSE: ABBV );
- Stelara by Janssen (owned by JNJ); and
- Fiasp, Fiasp FlexTouch, Fiasp PenFill, NovoLog, NovoLog FlexPen, NovoLog PenFill by Novo Nordisk (NYSE: NVO ).
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.